Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb232018	Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy $4.0 Million Awarded by CIRM to Support Advancement of First-of-Kind NK Cell Product Candidate derived from a Master Engineered iPSC Line SAN DIEGO , Feb. 23, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of Read All »	View HTML
Toggle SummaryNov012018	Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting Three Oral and Four Poster Presentations Covering Product Pipeline Accepted for Presentation Company to Host Investor Event at ASH on November 30 SAN DIEGO , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the Read All »	View HTML
Toggle SummarySep172018	Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform SAN DIEGO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed Read All »	View HTML
Toggle SummaryOct042018	Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations SAN DIEGO , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Wen Bo Wang , Ph.D., a leading expert in the manufacture of Read All »	View HTML
Toggle SummarySep132018	Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming New Approach Uses CRISPR-mediated Genome Activation for iPSC Generation SAN DIEGO , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune Read All »	View HTML
Toggle SummaryDec042018	Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting FT500, First-ever iPSC-derived Cell Product Candidate Cleared for U.S. Clinical Investigation by FDA, Featured in Oral Presentation SAN DIEGO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of Read All »	View HTML
Toggle SummaryMay102018	Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 Submission Read All »	View HTML
Toggle SummaryMar052018	Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow All Subjects in PROTECT Phase 1 Study of ProTmune Achieve Day 100 Relapse-free Survival Clinical-scale Production of FT500 Off-the-Shelf NK Cell Cancer Immunotherapy Initiated Read All »	View HTML
Toggle SummaryAug062018	Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress Treated 20 th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study Submitted First-of-Kind IND to FDA for Universal Off-the-Shelf NK Cell Product FT500 Licensed Novel CAR Constructs from Memorial Sloan Kettering Cancer Center for Off-the-Shelf Read All »	View HTML
Toggle SummaryNov012018	Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100 Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical Completed $144M Common Stock Public Offering Three Oral and Four Poster Presentations Covering Product Pipeline will be Presented at ASH Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.